A Millirobot Can Navigate a Beating Heart With Sub-Millimeter Accuracy | NEXAIRI

What is a magnetic millirobot, and how does it move without being connected to anything?

A magnetic millirobot is a small device — in the millimeter range — that contains magnetic material and is steered remotely through external electromagnetic fields, with no physical tether required.

Picture a capsule roughly the size of a grain of rice. It contains a carefully designed arrangement of magnetic material. Outside the body — or outside the lab phantom replicating a body — sits a set of electromagnetic coils. By varying the current through those coils in precise sequences, the system generates directed magnetic fields that push and pull the robot along a planned path. There are no cables running through the bloodstream. The robot moves because the field moves, and the field is controlled by the coil array.

The challenge is that magnetic control works well in static conditions — push a magnet from outside, the robot moves predictably. The problem is that inside a beating heart, nothing is static. Blood moves in pulses. Every heartbeat sends a surge of flow. The robot is constantly being pushed off course by forces that aren't uniform, aren't predictable from cycle to cycle, and change character depending on viscosity, flow rate, and the geometry of where the robot is in the cardiac chamber at any given moment. Controlling a device under those conditions requires something more sophisticated than a simple "go here" command.

Why is navigating inside a beating heart an extreme engineering challenge?

Blood doesn't flow steadily. It pulses with every heartbeat — and each pulse creates turbulent, time-varying forces that throw off standard navigation controllers designed for stable environments.

The engineering term for this is pulsatile flow. The heart contracts and relaxes roughly 60 to 100 times per minute. Each contraction pumps blood outward in a pressure wave. Inside the chambers and vessels, this creates a rapid acceleration followed by deceleration, with turbulence patterns that vary based on heart rate, blood pressure, vessel geometry, and the local viscosity of the fluid. In a real cardiac environment, blood viscosity itself varies — the researchers tested conditions at both 4.3 cP (close to real blood in thin-flowing states) and 20 cP (closer to the viscous end).

Standard control methods — PID controllers, which are the workhorse of industrial automation — work by measuring error (how far you are from target) and adjusting thrust to reduce it. PID does well in stable environments where disturbances are small. Under pulsatile cardiac flow, the disturbances aren't small. They're large, fast, and periodic. A PID controller tuned for smooth conditions will over-correct, oscillate, and eventually fail to maintain position when the flow surges against it.

Model predictive control (MPC) improves on PID by simulating future states and planning ahead — but it requires an accurate model of the disturbance to predict it. In a beating heart, the flow is only partially predictable. MPC performs better than PID but still struggles when the actual disturbance deviates from the model. The Johns Hopkins team's answer was a controller that could handle what it didn't fully predict.

How does the AI controller handle the turbulence of blood flow?

The team used a sliding mode controller with a disturbance observer — a control architecture that compensates for disturbances it can't model by estimating them in real time.

A sliding mode controller (the SMC part) works by driving the system toward a target trajectory and then keeping it on that trajectory even under external force. Once the system reaches its "sliding surface" — the intended path — the controller switches very rapidly between states to maintain it. This makes the controller robust by design: it doesn't need to predict the exact disturbance, it just continually corrects. The weakness of basic sliding mode control is chattering — those rapid switches can cause mechanical oscillation that's damaging in physical systems.

The disturbance observer (DOB) component addresses this. It estimates the disturbance force in real time — making an educated guess about what the flow is doing to the robot right now — and feeds that estimate into the control signal as a feedforward correction. The controller doesn't wait to see the error before acting; it adjusts preemptively based on its current disturbance estimate. The combination of sliding mode robustness and disturbance feedforward produced the accuracy gains the team reported.

The robot localization uses a UNet-based neural network — a convolutional architecture originally developed for biomedical image segmentation — to detect the robot's position from camera feeds in real time. Path planning runs through A*, a classical algorithm for finding optimal paths in a grid space. The full pipeline is: detect position via UNet, plan next move via A*, execute that move via the SMC-DOB controller, repeat at each time step. The loop runs fast enough to handle the cardiac flow dynamics.

Source: arXiv 2604.01523 — "Robust Autonomous Control of a Magnetic Millirobot in In Vitro Cardiac Flow," Bhattacharjee et al., April 2, 2026.

What would this technology actually be used for in clinical settings?

The primary target application is targeted drug delivery — placing therapeutic agents directly at a cardiac lesion site without open surgery or a catheter.

Heart disease remains the leading cause of death globally. Many cardiac interventions today require either open surgery — high risk, long recovery — or catheter-based procedures, which thread a flexible tube through blood vessels to the target site. Catheters are less invasive than open surgery but still require a physical device to navigate the vasculature, and their size limits how far they can reach into smaller vessels and chambers. A freely navigating millirobot changes that constraint: the robot goes where catheters can't easily fit, without any physical connection that limits maneuverability.

Drug delivery is the first target because it's the simplest action: the robot carries a payload to a specific location and releases it there. Future applications the research team discusses include targeted ablation therapy (destroying small lesions with heat or cold without damaging surrounding tissue), biopsy (withdrawing a small tissue sample from an inaccessible site), and stent placement in micro-vessels where current tools don't reach. None of these are near-term clinical applications. They represent a research roadmap, not a product timeline.

How far away is this from treating real patients?

This is a lab-phantom result — tested in a mechanical simulation of a heart, not in living tissue.

Before any human application, the technology must pass animal studies, biocompatibility testing, and regulatory review. That path takes years.

The distinction between "in vitro" and "in vivo" matters enormously here. In vitro means in a controlled laboratory environment — in this case, a heart phantom: a physical device that pumps fluid through artificial chambers at physiologically realistic pressures and flow rates. It's a carefully designed approximation of a heart, not a heart. The geometry is simplified. The fluid doesn't clot. The walls don't respond to contact. The robot doesn't need to avoid nerves, valve structures, or the irregular anatomy that varies from patient to patient.

The path from phantom to patient has several sequential gates. First, animal studies: the robot and its control system must work in living cardiac tissue, where the environment is far less predictable than a phantom. Second, biocompatibility: every surface material, coating, and component that could contact blood must be verified not to trigger clotting, immune response, or tissue damage. Third, the release mechanism for drug delivery must be validated — the robot needs to release its payload at the right location, at the right rate, without contaminating surrounding tissue. Fourth, regulatory clearance: devices that operate inside the heart fall under the FDA's most stringent approval pathways in the US, and equivalent bodies in other jurisdictions.

The researchers are explicit about these steps. The paper positions this work as a demonstration of feasibility for autonomous navigation in cardiac flow — a necessary precursor to clinical work, not clinical work itself. That's an important distinction to carry out of any "AI in medicine" story.